Skip to content
About Group
Careers
Contact Us
EN
FA
About Actoverco
About Actoverco
dv-sub
History
Actoverco and Covid
Goals and Strategies
Honors and Certificates
Export and Presence in Global Markets
Our Family
Our Family
dv-sub
Pharmaceutical Group Introduction
Food Industry Group Introduction
Production and Research Sites
Our Business Partners
Social Responsibility
Products
Product Brochure
cat1
All Products
Infectious Disease Drugs
Respiratory Drugs
Gastrointestinal Drugs
Kidney and Urinary Tract Drugs
MS Drugs
Neurological Drugs
Psychiatric medication
cat2
Gynecological Drugs
Skin and Hair Drugs
Cardiovascular Drugs
Transplant and Cancer Drugs
Diabetes Drugs
Pain Relievers
Merck Products
Other Drugs
Multimedia
Multimedia
dv-sub
Pictures Gallery
Videos Gallery
Exhibition Presences
Group Introduction
Updates
Updates
dv-sub
News
Special Contents
Events
Statements
Health Topics
About Actoverco
About Actoverco
dv-sub
History
Actoverco and Covid
Goals and Strategies
Honors and Certificates
Export and Presence in Global Markets
Our Family
Our Family
dv-sub
Pharmaceutical Group Introduction
Food Industry Group Introduction
Production and Research Sites
Our Business Partners
Social Responsibility
Products
Product Brochure
cat1
All Products
Infectious Disease Drugs
Respiratory Drugs
Gastrointestinal Drugs
Kidney and Urinary Tract Drugs
MS Drugs
Neurological Drugs
Psychiatric medication
cat2
Gynecological Drugs
Skin and Hair Drugs
Cardiovascular Drugs
Transplant and Cancer Drugs
Diabetes Drugs
Pain Relievers
Merck Products
Other Drugs
Multimedia
Multimedia
dv-sub
Pictures Gallery
Videos Gallery
Exhibition Presences
Group Introduction
Updates
Updates
dv-sub
News
Special Contents
Events
Statements
Health Topics
Search
Search...
Close
FA
About Actoverco
History
Actoverco and Covid
Goals and Strategies
Honors and Certificates
Export and Presence in Global Markets
Our Family
Pharmaceutical Group Introduction
Food Industry Group Introduction
Production and Research Sites Introduction
Our Business Partners
Social Responsibility
Products
Infectious Diseases
Respiratory Drugs
Gastrointestinal Drugs
Kidney and Urinary Tract Drugs
MS Drugs
Gynecological Drugs
Skin and Hair Drugs
Cardiovascular Drugs
Transplant and Cancer Drugs
Diabetes Drugs
Merck Products
Multimedia
Pictures Gallery
Videos Gallery
Exhibition Presences
Catalog
Updates
News
Special Contents
Events
Statements
Contact us
Contact Us
Career Opportunities
Health Topics
About Actoverco
History
Actoverco and Covid
Goals and Strategies
Honors and Certificates
Export and Presence in Global Markets
Our Family
Pharmaceutical Group Introduction
Food Industry Group Introduction
Production and Research Sites Introduction
Our Business Partners
Social Responsibility
Products
Infectious Diseases
Respiratory Drugs
Gastrointestinal Drugs
Kidney and Urinary Tract Drugs
MS Drugs
Gynecological Drugs
Skin and Hair Drugs
Cardiovascular Drugs
Transplant and Cancer Drugs
Diabetes Drugs
Merck Products
Multimedia
Pictures Gallery
Videos Gallery
Exhibition Presences
Catalog
Updates
News
Special Contents
Events
Statements
Contact us
Contact Us
Career Opportunities
Health Topics
Search
جستجو
Close
Visual Report on the Introduction of “gynati” and “prequin”
Author:
Actoverco
Date:
10 August 2024
Related Posts
Visual Report on the Introduction of “gynati” and “prequin”
10 August 2024
Visual Report on the Introduction of Actonib and Its application in Dermatology
31 July 2024
Neurostyle Launch Event
14 July 2024
Interview with Nahaleh Naraqi about Actoverco social responsibilities
5 June 2024
Dr. Zali, Commander of the Capital Corona Disease Management Operation, visited the Actover Group
8 February 2022
×
Scroll To Top
